BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 15, 2004
View Archived Issues
Adolor's Stock Suffers After Last Entereg Phase III Fails
Despite mediocre results from their fourth Phase III trial, Adolor Corp. and partner GlaxoSmithKline plc expect to seek regulatory approval this year for Entereg in the management of postoperative ileus. (BioWorld Today)
Read More
Amgen's CEO Chides Leaders For 'Hiding' From Ethics Fray
Read More
OxiGene Gets $22.3M, Plans Expansion Of CA4P Program
Read More
Enanta Raises $12M To Further Macrolide Respiratory Program
Read More
Other News To Note
Read More